Eric A. Wold
Affiliations: | University of Texas Medical Branch, Galveston, TX |
Area:
Medicinal Chemistry, 5-HT2C Receptor, CNS Drug DiscoveryGoogle:
"Eric A. Wold UTMB"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chen J, Garcia EJ, Merritt CR, et al. (2023) Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT Receptor and Dual 5-HT/5-HT Receptor Modulators. Journal of Medicinal Chemistry |
| Liu Z, Li Y, Chen H, et al. (2022) Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. Journal of Medicinal Chemistry |
| Liu Z, Wang P, Wold EA, et al. (2021) Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. Journal of Medicinal Chemistry |
| Xu J, Berastegui-Cabrera J, Carretero-Ledesma M, et al. (2021) Discovery of a Small Molecule Inhibitor of Human Adenovirus Capable of Preventing Escape from the Endosome. International Journal of Molecular Sciences. 22 |
| Ye N, Qin W, Tian S, et al. (2020) Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. Journal of Medicinal Chemistry |
| Wold EA, Garcia EJ, Wild C, et al. (2020) Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor Positive Allosteric Modulators with Enhanced Drug-Like Properties. Journal of Medicinal Chemistry |
| Liu Z, Chen H, Wang P, et al. (2020) Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffolding Hopping, Optimization and Pharmacological Evaluation. Journal of Medicinal Chemistry |
| Wold EA, Wild CT, Cunningham KA, et al. (2019) Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development. Current Topics in Medicinal Chemistry |
| Liu G, Yin T, Kim H, et al. (2019) Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. European Journal of Medicinal Chemistry. 178: 589-605 |
| Liu G, Wold EA, Zhou J. (2019) Applications of Bioorthogonal Chemistry in Tumor-Targeted Drug Discovery. Current Topics in Medicinal Chemistry |